Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study

Wei-Bin Wu, Ya-Wen Luo, Siqi Li, Lanping Xu, Yu Wang, Xiaohui Zhang, Yuqian Sun, Feifei Tang, Xiaodong Mo, Kai-Yan Liu, Xiao-Su Zhao, Xiang-Yu Zhao, He-Bing Chen, Ying-Jun Chang, Xiaojun Huang

Blood (2024) 144 (Supplement 1): 1834.

https://doi.org/10.1182/blood-2024-207920

Published: 2024

Journal Articles

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 623.

https://doi.org/10.1182/blood-2023-179160

Published: 2023

Journal Articles

Modulation of Biomarkers By BET Inhibitor, BMS-986158, Including JAK2 Variant Allele Frequency (VAF), Bone Marrow (BM) Fibrosis, and Reversal of Abnormal Cytokine Production in Intermediate- or High-Risk Myelofibrosis (MF)

Si Tuen Lee-Hoeflich, Christopher Brueckner, Lawrence Litalien, Ke Xu, Sharmila Das, Laura Corella, Sherif Daouti, Oriana Esposito, Emma Lees, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, Bin Wu

Blood (2023) 142 (Supplement 1): 3158.

https://doi.org/10.1182/blood-2023-181620

Published: 2023

Journal Articles

BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study

Blood (2022) 140 (Supplement 1): 9665–9667.

https://doi.org/10.1182/blood-2022-159476

Published: 2022

Journal Articles

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Blood (2021) 137 (13): 1792–1803.

https://doi.org/10.1182/blood.2020007233

Published: 2021

Includes: Supplemental data

Journal Articles

Longitudinal Molecular Profiling in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Sung Choe, PhD, Hongfang Wang, PhD, Gail J. Roboz, MD, Courtney D. DiNardo, MD MSCE, Eytan M. Stein, MD, Alice S. Mims, MD, Gabrielle T. Prince, MD, Justin M. Watts, MD, Bin Fan, PhD, Parham Nejad, BSc, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD, Richard M. Stone, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136589

Published: 2020

Journal Articles

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Blood (2020) 136 (Supplement 1): 49–51.

https://doi.org/10.1182/blood-2020-136922

Published: 2020

Journal Articles

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1 -mutant acute myeloid leukemia

Blood (2020) 135 (7): 463–471.

https://doi.org/10.1182/blood.2019002140

Published: 2020

Includes: Supplemental data

Journal Articles

Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses

Hongfang Wang, PhD, Sung Choe, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stéphane de Botton, MD PhD, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 541.

https://doi.org/10.1182/blood-2019-122703

Published: 2019

Journal Articles

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

Sung Choe, PhD, Hongfang Wang, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Zenon Konteatis, PhD, Lenny Dang, PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 545.

https://doi.org/10.1182/blood-2019-122671

Published: 2019

Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 4254.

https://doi.org/10.1182/blood-2019-123946

Published: 2019

Journal Articles

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Scott R. Daigle, MS, Sung Choe, PhD, Lynn Quek, MD PhD, Courtney D. DiNardo, MDMSc, Anthony Stein, MD, Eytan M. Stein, MD, Amir T. Fathi, MD, Olga Frankfurt, MD, Andre C. Schuh, MD, Hagop M. Kantarjian, MD, Vickie Zhang, PhD, Thomas Winkler, MD, Paresh Vyas, MD PhD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 2706.

https://doi.org/10.1182/blood-2019-122590

Published: 2019

Journal Articles

Molecular remission and response patterns in patients with mutant- IDH2 acute myeloid leukemia treated with enasidenib

Blood (2019) 133 (7): 676–687.

https://doi.org/10.1182/blood-2018-08-869008

Published: 2019

Includes: Supplemental data

Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

Blood (2018) 132 (Supplement 1): 1812.

https://doi.org/10.1182/blood-2018-99-111264

Published: 2018

Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Blood (2018) 132 (Supplement 1): 561.

https://doi.org/10.1182/blood-2018-99-110595

Published: 2018

Journal Articles

Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML

Richard M. Stone, MD, Sung Choe, PhD, Vickie Zhang, PhD, Benoit Marteyn, PhD, Virginie Penard-Lacronique, PhD, Hongfang Wang, PhD, Courtney D. DiNardo, MDMSc, Eytan M. Stein, MD, Amir T. Fathi, MD MD BS, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Eyal C. Attar, MD, Bin Wu, Stephane de Botton, MD PhD

Blood (2017) 130 (Supplement 1): 2684.

https://doi.org/10.1182/blood.V130.Suppl_1.2684.2684

Published: 2017

Journal Articles

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Michael D. Amatangelo, Lynn Quek, Alan Shih, Eytan M. Stein, Mikhail Roshal, Muriel D. David, Benoit Marteyn, Noushin Rahnamay Farnoud, Stephane de Botton, Olivier A. Bernard, Bin Wu, Katharine E. Yen, Martin S. Tallman, Elli Papaemmanuil, Virginie Penard-Lacronique, Anjan Thakurta, Paresh Vyas, Ross L. Levine

Blood (2017) 130 (6): 732–741.

https://doi.org/10.1182/blood-2017-04-779447

Published: 2017

Includes: Supplemental data

Journal Articles

Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1

Blood (2016) 128 (22): 1070.

https://doi.org/10.1182/blood.V128.22.1070.1070

Published: 2016

Journal Articles

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

Courtney DiNardo, MD, Stéphane de Botton, Daniel A Pollyea, Eytan M Stein, Amir T. Fathi, MD, Gail J Roboz, MD, Robert Collins, MD, Ronan T. Swords, MDPhDFRCPI FRCPath, Ian W. Flinn, MD PhD, Jessica K Altman, Martin S Tallman, MD, Hagop M. Kantarjian, MD, Adnan Derti, Meredith Goldwasser, Malia Prahl, Bin Wu, Katharine Yen, Sam Agresta, Richard M. Stone, MD

Blood (2015) 126 (23): 1306.

https://doi.org/10.1182/blood.V126.23.1306.1306

Published: 2015

Journal Articles

Different Strategies for First-Line Treatment of Chronic Myeloid Leukaemia: An Economic Analysis

Bin Wu, Hua Zhong, Giuseppe Saglio, MD, Fangyuan Chen

Blood (2012) 120 (21): 4696.

https://doi.org/10.1182/blood.V120.21.4696.4696

Published: 2012

NARROW

Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Modulation of Biomarkers By BET Inhibitor, BMS-986158, Including JAK2 Variant Allele Frequency (VAF), Bone Marrow (BM) Fibrosis, and Reversal of Abnormal Cytokine Production in Intermediate- or High-Risk Myelofibrosis (MF)

BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Longitudinal Molecular Profiling in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1 -mutant acute myeloid leukemia

Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Molecular remission and response patterns in patients with mutant- IDH2 acute myeloid leukemia treated with enasidenib

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

Different Strategies for First-Line Treatment of Chronic Myeloid Leukaemia: An Economic Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only